Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -216.38
- Piotroski Score 0.00
- Grade Buy
- Symbol (PTN)
- Company Palatin Technologies, Inc.
- Price $0.97
- Changes Percentage (3.38%)
- Change $0.03
- Day Low $0.92
- Day High $0.98
- Year High $5.65
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.72
- Trailing P/E Ratio -0.69
- Forward P/E Ratio -0.69
- P/E Growth -0.69
- Net Income $-29,736,113
Income Statement
Quarterly
Annual
Latest News of PTN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance
Full year 2024 operating expenses guidance revised to $90-$93 million. CFO explains conservative Q4 guidance due to inventory stocking impact in Q3. CEO notes most insurance plans updated coverage for...
By Yahoo! Finance | 1 week ago -
SpartanNash Co (SPTN) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...
SpartanNash's private label segment showed stable performance, with a focus on premium and value options like Our Family and Finest Reserve brands. Two recent acquisitions align with the company's gro...
By Yahoo! Finance | 2 weeks ago -
Is Cepton, Inc. (CPTN) a Good Lidar Stock To Buy?
The article discusses Cepton, Inc. (NASDAQ:CPTN) and its position among the top Lidar stocks. It highlights the growth potential of the Lidar industry and emphasizes financial metrics and technologica...
By Yahoo! Finance | 1 month ago
